Astellas bets $1.89B on Aussie drug
Astellas Pharma has agreed to pay up to US$1.34 billion (AUD$1.89 billion) for rights to develop and commercialise Melbourne start-up Audax Biosciences’ pre-clinical immuno-oncology asset.
To see the whole article, log in or create an account.